厄贝沙坦联合氨氯地平对糖尿病高血压合并高尿酸血症患者降压及降尿酸疗效的Meta分析

Clinical effects of combination of irbesartan and amlodipine on hypertension and Uric acid in patients with diabetes,hypertension and hyperuricemia: a Meta-analysis

目的评价厄贝沙坦联合氨氯地平对糖尿病高血压合并高尿酸血症患者控制血压及血尿酸的效果。方法检索"中国知网""万方数据库""维普数据库"2012年1月至2017年7月的文献,查找厄贝沙坦联合氨氯地平治疗糖尿病高血压合并高尿酸血症患者的随机对照试验的中文文献。提取相关数据并应用Stata13.0软件进行Meta分析。结果共纳入10篇中文文献,共有糖尿病高血压合并高尿酸血症患者1029例,其中联合用药组有477例,厄贝沙坦组244例,氨氯地平组308例。经6个月治疗后,联合用药组的收缩压及尿酸水平均低于单独用药组(均差异有统计学意义,P<0.05)。结论厄贝沙坦联合氨氯地平对糖尿病高血压合并高尿酸血症患者的血压及尿酸控制效果是高于单独用药的。

Objective To estimate the clinical effect of combination of irbesartan and amlodipine on hypertension and Uric acid in patients with diabetes,hypertension and hyperuricemia. Methods The randomized controlled trials( RCTs) were searched in CNKI,wanfang database and VIP detabase. Datas were selected and extracted. Stata 13. 0 statistical software was used for Meta-analysis. Results Ten RCTs were selected into this Meta-analysis with 1029 cases in total,477 in drug combination group,244 in irbesartan group and 308 in amlodipine group. Meta-analysis showed that blood pressures and Uric acid in trail group were lower than those in control group after 6 months treament( P < 0. 05).Conclusion Combination therapy is more effective in reducing hypertension and uric acid level for patients with diabetes,hypertension and hyperuricemia.